1. HBW Insight
  2. >>Digital Technologies

VeriSIM Expects AI Use To Trim Margin For Failure In OTC Switches, Help Boost Revenue Margins

 
• By Malcolm Spicer

“It's a very expensive process for an OTC drug because you don't make significantly high margins compared to a blockbuster cancer drug. For pharma companies utilizing our platform, you can reduce that efficiency challenge and increase the probability of success,” says VeriSIM CEO Jo Varshney.

• Source: Shutterstock

Expectations for artificial intelligence’s use in pharma research typically skew heavily on ingredients which would be Rx-only, but firms looking at making additional drugs available OTC could have as much or more to gain.

Jo Varshney, founder and CEO of AI startup VeriSIM Life Inc., recently told HBW Insight that firms moving ingredients from...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Digital Technologies

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, home of HBW Insight, to focus on AI, business harmonization and long-term growth.

Value Of Consumer Wearables Within The Clinic Currently Unknown, Says Cardiologist

 
• By Natasha Barrow

“It’s quite likely [consumer wearable manufacturers] are changing the sensitivity and specificity based on consumer feedback, but not for medical reasons,” said Dipak Kotecha, a University of Birmingham professor of cardiology. Often, self-reported performance evidence from manufacturers is “low quality and biased.”

Bayer Study Shows Potential Of Saliva-Based Biomarker For Healthy Aging

 
• By David Ridley

Bayer Consumer Health hopes its new InflammAge saliva-based biomarker can help “revolutionize self-care and how people can manage their aging journey.”

Church & Dwight Launching Sugar-Free Vitafusion, Looks To AI As Sweet Spot For All Growth

 
• By Malcolm Spicer

AI prowess “will not be a competitive advantage long-term. It's going to be table stakes. But there are people who are going to get there sooner and they will have an advantage for a while,” says C&D CEO Matthew Farrell. P&G’s investment in AI, meanwhile, produced its “Great Idea Generator proprietary platform.”

More from HBW Insight

People On The Move: Appointments At Enzymatica, Haleon, Futura

 
• By Tom Gallen

A round up of the latest moves in Europe's consumer health market: Enzymatica appoints CEO; Haleon hires DACH marketing chief; Futura confirms interim CEO.

Industry Pleased To See Self-Care In Revised English Children’s Education Policy

 
• By David Ridley

Children and young adults will in future learn more about responsible self-care, including when it is appropriate to see a pharmacist, specific instructions for dental health and information about health risks associated with smoking, vaping, and other nicotine products such as nicotine pouches.

US Tax Code Already Spells Using HSA/FSAs For Dietary Supplement Purchases, NPA Tells IRS

 
• By Malcolm Spicer

Internal Revenue Code should include within its definition of “medical care” spending the consumers' purchases of supplement products based on labeling of FDA-approved health and structure/function claims, NPA CEO Daniel Fabricant says.